Related Experiment Videos
Early or late ACE inhibition after myocardial infarction
1Department of Cardiovascular Studies, University of Leeds, England.
Insights
Angiotensin-converting enzyme (ACE) inhibitors show promise for heart failure patients. However, their benefit after acute myocardial infarction hinges on balancing ischemia against ventricular function preservation.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Angiotensin-converting enzyme (ACE) inhibitors are frequently used for heart failure.
- The role of ACE inhibitors early after acute myocardial infarction (AMI) requires careful consideration.
Purpose of the Study:
- To evaluate the potential benefits and harms of ACE inhibitors in the acute phase following myocardial infarction.
- To determine the optimal patient profile for ACE inhibitor therapy in the context of AMI.
Main Methods:
- Review of existing literature and clinical trial data regarding ACE inhibitor use in heart failure and acute myocardial infarction.
- Analysis of the interplay between ischemic burden and ventricular function in AMI patients.
Main Results:
- Patients with hemodynamically stable conditions, no ongoing chest pain, and significantly impaired ventricular function may benefit most from ACE inhibitors post-MI.
- Extrapolation of findings from chronic heart failure trials to the acute MI setting may be misleading.
Conclusions:
- The precise benefit or harm of ACE inhibitors in acute myocardial infarction is context-dependent.
- Further data from ongoing mortality trials in recent myocardial infarction patients are needed to clarify optimal treatment strategies.
Abstract:
There is justifiable enthusiasm for the use of angiotensin-converting enzyme (ACE) inhibitors in patients with heart failure. However, early after an acute myocardial infarction, the benefits (or harm) from use of these agents in individual patients may depend on the critical balance between the ischemic problem (the extent of coronary artery narrowing and risk of vessel occlusion) against the need to preserve remaining ventricular function. Patients who are hemodynamically stable without ongoing chest pain but with significantly impaired ventricular function seem likely to gain most from treatment with ACE inhibitors. Extrapolation to the acute infarct situation from the recently published trials in chronic stable heart failure may mislead, and the findings of a number of large ongoing mortality trials in patients with recent myocardial infarction are awaited.